The BioPharm Brief: Investments in Next-Gen Modalities Drive Oncology and Metabolic Therapy Development

Mar 19, 06:45 PM
Headliner
Share
Subscribe

Welcome to The BioPharm Brief, your daily snapshot of key developments in biopharmaceutical research, innovation, and clinical progress. Today’s update highlights fresh funding for T‑cell engager platforms and continued momentum in multi‑agonist metabolic therapy development.

Share
Subscribe
Next
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief